June 11, 2021 7:40am

But, is not immune to being downtrodden

Pre-open indications: 6 BUYs: EDIT, BLUE, GBT, PGEN, RGNX, SAGE; 1 SELL:  PSTI; 1 Maintain SELLs: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! 

 


Dow futures are up +0.21% (+73 points), S&P futures are up +0.15% (+6 point) and NASDAQ futures are up +0.20% (+28 points)

 

U.S. stock futures are up in pre-market trade Friday morning,

European markets were marginally higher,

Asia-Pacific markets were muted in overnight trade.

 

Henry’omics:

There were not many big movers in premarket trading.

For the week, major benchmarks are mixed. The Dow is off by 0.8%, but the S&P 500 is up 0.2% and the Nasdaq Composite is up 1.5%.

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … thirty (32 – MESO added) to date …  https://www.regmedinvestors.com/articles/11628

 

Thursday’s evening’s recap: “the trend is still the cell and gene therapy’s sector friend. We accept volatility when it’s in our favor until it isn’t.” … https://www.regmedinvestors.com/articles/11950

  • The Nasdaq closed UP +108.58 points (+0.78%);
  • The IBB closed up +1.69% and XBI closed up +1.02%
  • Sector volume was WEAK with 2 of the 26-upside having higher than the 3-month average volume The CBOE Volatility Index (VVIX: INDEX) tracked:
  • The CBOE Volatility Index (VVIX: INDEX) was down -1.79 points or -10.01% at 16.10;
  • Thursday’s percentage (%) of the 26-upside were +0.33% (QURE) to +6.70% (FATE) while the 7-downside ranges from -0.23% (AGTC) to -4.82% (RENE.L);

Q2/21:

June: 6 positive and 2 negative close

May:  8 positive, 12 negative closes and 1 holiday

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell – It’s about saying WHAT NEEDS to be written …

Biostage (BSTG) closed up +$0.01 to $1.21 with 1,325 shares traded after Wednesday’s +$0.13 to $1.26 with 1,216 shares traded.

Question#`1: Notice the volume numbers per session? WHY the need to “pump, promote and inflate” the share price; does the volume reflects the manipulation to execute the last remaining warrants?

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

BUY:

bluebird bio (BLUE) closed up +$0.92 to $33.89 and has positive +$0.61 or +1.80$ pre-market indication after presenting data from several studies of betibeglogene autotemcel (beti-cel) gene therapy (licensed as ZYNTEGLO™ in the EU and UK) in adult, adolescent and pediatric patients with transfusion-dependent β-thalassemia (TDT). These data were presented during EHA2021 Virtual, the 26th Annual Congress of the European Hematology Association, taking place June 9-17, 2021.

  • The absence of drug product-related adverse events beyond two years post-infusion supports a favorable long-term safety profile of beti-cel
  • Data from BLYE’s P1/2 and P3 clinical studies represent more than 220 patient-years of experience with beti-cel

 

Editas Medicine (EDIT) closed up +$0.50 to $36.90 and has a positive +$1.39 or +3.77% pre-market indication; announcing pre-clinical data supporting the initiation of the EDIT-301 P1/2 RUBY clinical trial to evaluate EDIT-301, a one-time, durable, autologous cell therapy medicine to treat sickle cell disease. EDIT-301 is the first experimental medicine generated using CRISPR/Cas12a gene editing. EDIT reported the data in an oral presentation at the 26th Congress of the European Hematology Association (EHA) being held virtually.

Global Blood therapeutics (GBT) closed up +$1.25 to $41.67 and has a positive +$0.25 or +0.60% pre-market indication especially with new data from the P2a HOPE-KIDS 1 Study that showed children with sickle cell disease (SCD) ages 4 to 11 years treated with Oxbryta® (voxelotor) tablets experienced significant improvements in hemoglobin levels. These data, along with results from two real-world evidence studies of Oxbryta, will be presented at the European Hematology Association (EHA) 2021 Virtual Congress, taking place online June 9-17, 2021.

Precigen (PGEN) closed down -$0.18 to $6.99 and has a positive +$2.20 or +31.47 after news of Precigen ActoBio, a wholly-owned subsidiary of PGEN announced positive topline results for the ongoing P1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes (T1D) (clinical trial identifier: NCT03751007, EudraCT 2017-002871-24). Results from the primary analysis were presented at the Federation of Clinical Immunology Societies (FOCIS) 2021 Virtual Annual Meeting by Kevan Herold, MD, Professor of Immunobiology and of Medicine at the Yale University.

Regenxbio (RGNX) closed up +$0.36 to $37.77 and has a positive +$0.54 or +1.43% aftermarket indication.

Sage Therapeutics (SAGE) closed up +$0.92 to $76.09 after Wednesday’s +$0.41 to $75.17 and Tuesday’s +$4.29 to $74.76 SELL:

Pluristem (PSTI) closed flat at $4.32 and has a negative -$0.12 or 2.78% pre-market indication.

 

 

The BOTTOM LINE: News always helps the flow of share pricing however; higher share prices are just temporary or about to be deflated?

Wake-up volatility is NOT going away!

I continue to MAINTAIN, this is a confused sector as sentiment fades, momentum is usurped, fundamentals are being ignored – or is it a test of our staying power in certain equities.

It’s going be a long hot summer – expects the fizzle on stock pricing until it isn’t!

Although, “I would consider new highs … to be SOLD into …complacency is in store as many investors actually get out to vacations (one indicator).”

A true contrarian thought …

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.